Here’s what you should know:
1. Valeant has an 11-member board, 10 of those members are independent.
2. Mr. Paulson said in a release that he fully supports Valeant’s attempts to invest in its core products while, selling off non-core assets to de-lever the company.
3. Valeant CEO and President Joseph C. Papa said in a release, “We are pleased to welcome John to Valeant’s board of directors. With his significant business and financial expertise, John will be a strong addition to the board. His experience will be especially valuable as we continue to execute on our transformational strategy to turnaround Valeant.”
More articles on gastroenterology:
GI leader to know: Dr. David Schwartz of Vermont Gastroenterology
Exact Sciences pockets $238M from secondary stock sale — 3 key notes
Clarivate Analytics ranks AGA’s flagship magazine highest of 79 journals
